Hence, we have unraveled a superior combinatorial therapeutic strategy that involves targeting the canonical-autophagy-independent function of FIP200 along with ICB, to achieve prolonged durable responses in mice bearing mammary tumors that were otherwise unresponsive to ICB. Here, RB1CC1 is linked to breast cancer.